


In one aspect of the present disclosure, there is provided a compound represented by



or a pharmaceutically acceptable salt and/or stereoisomer thereof, wherein q is 1, 2 or 3 and when q is 2 or 3:

- 5 R¹ is independently selected from the group consisting of H, -C₁-C₆alkyl, -C(O)-C₁-C₆alkyl, and -S(O)_w-C₁-C₆alkyl, wherein C₁-C₆alkyl is optionally substituted by one, two or three substituents each independently selected from R^P;

w is 0, 1, or 2;

R⁶ is not present;

- 10 m is 0;

R³ is H; R^P is independently, for each occurrence, selected from the group consisting of -C(O)NR^aR^b, -NR^aR^b, hydroxyl, -SH, and halogen;

R^a and R^b are each independently, for each occurrence, selected from the group consisting of H, $-C_1-C_3$ alkyl, phenyl, and benzyl, wherein each C_1-C_3 alkyl, phenyl, and benzyl is optionally substituted by one, two or three substituents each independently selected from the group consisting of hydroxyl, C_1-C_3 alkyl, and halogen, and

5 when q is 1:

R^1 is independently selected from the group consisting of $-C(O)-C_1-C_6$ alkyl and $-S(O)_w-C_1-C_6$ alkyl, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P ;

w is 0, 1, or 2;

10 R^6 is not present;

m is 0;

R^3 is H;

R^P is independently, for each occurrence, selected from the group consisting of $-C(O)NR^aR^b$, $-NR^aR^b$, hydroxyl, $-SH$, and halogen; and

15 R^a and R^b are each independently, for each occurrence, selected from the group consisting of H, $-C_1-C_3$ alkyl, phenyl, and benzyl, wherein each C_1-C_3 alkyl, phenyl, and benzyl

is optionally substituted by one, two or three substituents each independently selected from the group consisting of hydroxyl, C₁-C₃alkyl, and halogen.

In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising the compound disclosed herein, or a pharmaceutically acceptable salt
5 and/or a stereoisomer thereof, and a pharmaceutically acceptable excipient.

In a further aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the pharmaceutical composition disclosed herein, in the manufacture of a medicament for treating depression, Alzheimer's disease, attention deficit disorder, schizophrenia, or anxiety, in a
10 patient in need thereof.


In another aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the pharmaceutical composition disclosed herein, in the manufacture of a medicament for treating a migraine in a patient in need thereof.

15 In a further aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the

CLAIMS

What is claimed is:

1. A compound represented by



or a pharmaceutically acceptable salt and/or stereoisomer thereof, wherein q is 1, 2 or 3 and when q is 2 or 3:

R^1 is independently selected from the group consisting of H, $-C_1-C_6$ alkyl, $-C(O)-C_1-C_6$ alkyl, and $-S(O)_w-C_1-C_6$ alkyl, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P ;

w is 0, 1, or 2;

R^6 is not present;

m is 0;

R^3 is H;

R^P is independently, for each occurrence, selected from the group consisting of $-C(O)NR^aR^b$, $-NR^aR^b$, hydroxyl, $-SH$, and halogen;

R^a and R^b are each independently, for each occurrence, selected from the group consisting of H, $-C_1-C_3$ alkyl, phenyl, and benzyl, wherein each C_1-C_3 alkyl, phenyl, and benzyl is optionally substituted by one, two or three substituents each independently selected from the group consisting of hydroxyl, C_1-C_3 alkyl, and halogen, and

when q is 1:

R^1 is independently selected from the group consisting of $-C(O)-C_1-C_6$ alkyl and $-S(O)_w-C_1-C_6$ alkyl, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P ;

w is 0, 1, or 2;

R^6 is not present;


m is 0;

R^3 is H;

R^P is independently, for each occurrence, selected from the group consisting of $-C(O)NR^aR^b$, $-NR^aR^b$, hydroxyl, $-SH$, and halogen; and

R^a and R^b are each independently, for each occurrence, selected from the group consisting of H, $-C_1-C_3$ alkyl, phenyl, and benzyl, wherein each C_1-C_3 alkyl, phenyl, and benzyl is optionally substituted by one, two or three substituents each independently selected from the group consisting of hydroxyl, C_1-C_3 alkyl, and halogen.

2. The compound of claim 1, wherein the compound is represented by:



or a pharmaceutically acceptable salt and/or a stereoisomer thereof, wherein:

R^1 is $-C(O)-C_1-C_6$ alkyl, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P ;


R^3 is H;

R^P is independently, for each occurrence, selected from the group consisting of $-C(O)NR^aR^b$, $-NR^aR^b$, hydroxyl, $-SH$, and halogen; and

R^a and R^b are each independently, for each occurrence, selected from the group consisting of H, $-C_1-C_3$ alkyl, phenyl, and benzyl, wherein each C_1-C_3 alkyl, phenyl, and benzyl is optionally substituted by one, two or three substituents each independently selected from the group consisting of hydroxyl, C_1-C_3 alkyl, and halogen.


3. The compound of claim 1 or 2, wherein R^1 is $-C(O)-C_1-C_4$ alkyl.

4. The compound of claim 1, selected from the group consisting of:



or a pharmaceutically acceptable salt and/or a stereoisomer thereof.

5. The compound of claim 1, represented by



or a pharmaceutically acceptable salt and/or a stereoisomer thereof.

6. A pharmaceutical composition comprising the compound of any one of claims 1-5, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, and a pharmaceutically acceptable excipient.

7. The pharmaceutical composition of claim 6, suitable for oral administration, parenteral administration, topical administration, intravaginal administration, intrarectal administration, sublingual administration, ocular administration, transdermal administration, or nasal administration.

8. Use of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the pharmaceutical composition of claim 6 or 7, in the manufacture of a medicament for treating depression, Alzheimer's disease, attention deficit disorder, schizophrenia, or anxiety, in a patient in need thereof.

9. Use of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the pharmaceutical composition of claim 6 or 7, in the manufacture of a medicament for treating a migraine in a patient in need thereof.

10. Use of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the pharmaceutical composition of claim 6 or 7, in the manufacture of a medicament for treating neuropathic pain in a patient in need thereof.

11. Use of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the pharmaceutical composition of claim 6 or 7, in the manufacture of a medicament for treating traumatic brain injury in a patient in need thereof.

12. Use of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the pharmaceutical composition of claim 6 or 7, in the manufacture of a medicament for treating a neurodevelopmental disorder related to synaptic dysfunction in a patient in need thereof.

13. Use of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the pharmaceutical composition of claim 6 or 7, in the

manufacture of a medicament for treating a cognitive impairment disorder in a patient in need thereof.

14. A compound of any one of claims 1-5, or a pharmaceutically acceptable salt and/or a stereoisomer thereof, or the pharmaceutical composition of claim 6 or 7, for use in treating depression, Alzheimer's disease, attention deficit disorder, schizophrenia, anxiety, migraine, neuropathic pain, traumatic brain injury, neurodevelopmental disorder related to synaptic dysfunction, or cognitive impairment disorder in a patient in need thereof.